+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rx/Reimbursement Adult Incontinence in Estonia

  • ID: 4517572
  • Report
  • June 2020
  • Region: Estonia
  • 18 pages
  • Euromonitor International
In 2019 rx/reimbursement adult incontinence experienced strong growth as Estonia is becoming closer to a welfare state, and Estonians facing incontinence issues visited doctors to obtain the documentation needed to get the products. The system is well embedded in local traditions, so the expectation for the forecast period remains in line with current performance. A supporting factor raising demand is the ageing population.

The Rx/Reimbursement adult incontinence in Estonia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2015-2019, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2024 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Rx/Reimbursement adult incontinence market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Note: Product cover images may vary from those shown
HEADLINES

PRE-COVID-19 PERFORMANCE
  • Ageing population drives growth in rx/reimbursement adult incontinence
  • Potential challenges in new regulations
  • Tena and Molimed remain the key players in rx/reimbursement adult incontinence
2020 AND BEYOND
  • COVID-19 impact
  • Affected products within RX/reimbursement adult incontinence
  • Recovery and opportunities
CATEGORY DATA
Table 1 Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP 2014-2019
Table 2 Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP Growth 2014-2019
Table 3 Forecast Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP 2019-2024
Table 4 Forecast Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP Growth 2019-2024

EXECUTIVE SUMMARY
  • COVID-19 impact on tissue and hygiene
  • COVID-19 country impact
  • Increasing purchasing power and demographic structure shape tissue and hygiene sales in 2019
  • Finnish brand on a mission to shake up tissue and hygiene in 2019
  • COVID-19 is likely to alter consumer behaviour in the long term
MARKET INDICATORS
Table 5 Birth Rates 2014-2019
Table 6 Infant Population 2014-2019
Table 7 Female Population by Age 2014-2019
Table 8 Total Population by Age 2014-2019
Table 9 Households 2014-2019
Table 10 Forecast Infant Population 2019-2024
Table 11 Forecast Female Population by Age 2019-2024
Table 12 Forecast Total Population by Age 2019-2024
Table 13 Forecast Households 2019-2024

MARKET DATA
Table 14 Retail Sales of Tissue and Hygiene by Category: Value 2014-2019
Table 15 Retail Sales of Tissue and Hygiene by Category: % Value Growth 2014-2019
Table 16 NBO Company Shares of Retail Tissue and Hygiene: % Value 2015-2019
Table 17 LBN Brand Shares of Retail Tissue and Hygiene: % Value 2016-2019
Table 18 Penetration of Private Label in Retail Tissue and Hygiene by Category: % Value 2014-2019
Table 19 Distribution of Retail Tissue and Hygiene by Format: % Value 2014-2019
Table 20 Distribution of Retail Tissue and Hygiene by Format and Category: % Value 2019
Table 21 Forecast Retail Sales of Tissue and Hygiene by Category: Value 2019-2024
Table 22 Forecast Retail Sales of Tissue and Hygiene by Category: % Value Growth 2019-2024

GLOBAL MACROECONOMIC ENVIRONMENT

GLOBAL INDUSTRY ENVIRONMENT

DISCLAIMER

SOURCES
Summary 1 Research Sources
Note: Product cover images may vary from those shown
Adroll
adroll